182 related articles for article (PubMed ID: 36683587)
1. Evaluating the Impact of Black Box Warning Updates on the Reporting of Drug-Related Adverse Events: a Cross Sectional Study of the FAERS Database.
Yavne Y; Amar Shamir R; Shapiro M; Shepshelovich D
Expert Opin Drug Saf; 2023; 22(6):463-468. PubMed ID: 36683587
[TBL] [Abstract][Full Text] [Related]
2. New and incremental FDA black box warnings from 2008 to 2015.
Solotke MT; Dhruva SS; Downing NS; Shah ND; Ross JS
Expert Opin Drug Saf; 2018 Feb; 17(2):117-123. PubMed ID: 29215916
[TBL] [Abstract][Full Text] [Related]
3. Complementing the US Food and Drug Administration Adverse Event Reporting System With Adverse Drug Reaction Reporting From Social Media: Comparative Analysis.
Zhou Z; Hultgren KE
JMIR Public Health Surveill; 2020 Sep; 6(3):e19266. PubMed ID: 32996889
[TBL] [Abstract][Full Text] [Related]
4. A Pharmacovigilance Study of Adverse Drug Reactions Reported for Cardiovascular Disease Medications Approved Between 2012 and 2017 in the United States Food and Drug Administration Adverse Event Reporting System (FAERS) Database.
Patel NM; Stottlemyer BA; Gray MP; Boyce RD; Kane-Gill SL
Cardiovasc Drugs Ther; 2022 Apr; 36(2):309-322. PubMed ID: 33599896
[TBL] [Abstract][Full Text] [Related]
5. An Audit of Black Box Warnings (BBWs) in the United States Food and Drug Administration (US-FDA) Database - A Five-Year Analysis.
Bose D; Gogtay N; Goel T; Konwar M
Curr Drug Saf; 2022; 17(1):54-58. PubMed ID: 34382527
[TBL] [Abstract][Full Text] [Related]
6. Impact of United States Food and Drug Administration's boxed warnings on adverse drug reactions reporting rates and risk mitigation for multiple myeloma drugs.
Garg V; Raisch DW; McKoy JM; Trifilio SM; Holbrook J; Edwards BJ; Belknap SM; Samaras AT; Nardone B; West DP
Expert Opin Drug Saf; 2013 May; 12(3):299-307. PubMed ID: 23480866
[TBL] [Abstract][Full Text] [Related]
7. Prediction of black box warning by mining patterns of Convergent Focus Shift in clinical trial study populations using linked public data.
Ma H; Weng C
J Biomed Inform; 2016 Apr; 60():132-44. PubMed ID: 26851401
[TBL] [Abstract][Full Text] [Related]
8. Traceability of biopharmaceuticals in spontaneous reporting systems: a cross-sectional study in the FDA Adverse Event Reporting System (FAERS) and EudraVigilance databases.
Vermeer NS; Straus SM; Mantel-Teeuwisse AK; Domergue F; Egberts TC; Leufkens HG; De Bruin ML
Drug Saf; 2013 Aug; 36(8):617-25. PubMed ID: 23771794
[TBL] [Abstract][Full Text] [Related]
9. Use of Disproportionality Analysis to Identify Previously Unknown Drug-Associated Causes of Cardiac Arrhythmias Using the Food and Drug Administration Adverse Event Reporting System (FAERS) Database.
Moreland-Head LN; Coons JC; Seybert AL; Gray MP; Kane-Gill SL
J Cardiovasc Pharmacol Ther; 2021 Jul; 26(4):341-348. PubMed ID: 33403858
[TBL] [Abstract][Full Text] [Related]
10. Drug-Associated Acute Kidney Injury Identified in the United States Food and Drug Administration Adverse Event Reporting System Database.
Welch HK; Kellum JA; Kane-Gill SL
Pharmacotherapy; 2018 Aug; 38(8):785-793. PubMed ID: 29883524
[TBL] [Abstract][Full Text] [Related]
11. Profiling cumulative proportional reporting ratios of drug-induced liver injury in the FDA Adverse Event Reporting System (FAERS) database.
Brinker AD; Lyndly J; Tonning J; Moeny D; Levine JG; Avigan MI
Drug Saf; 2013 Dec; 36(12):1169-78. PubMed ID: 24178291
[TBL] [Abstract][Full Text] [Related]
12. Data mining for adverse drug reaction signals of daptomycin based on real-world data: a disproportionality analysis of the US Food and Drug Administration adverse event reporting system.
Chen JJ; Huo XC; Wang SX; Wang F; Zhao Q
Int J Clin Pharm; 2022 Dec; 44(6):1351-1360. PubMed ID: 36178607
[TBL] [Abstract][Full Text] [Related]
13. Characterization of Pediatric Reports in the US Food and Drug Administration Adverse Event Reporting System from 2010-2020: A Cross-Sectional Study.
Phan M; Cheng C; Dang V; Wu E; Muñoz MA
Ther Innov Regul Sci; 2023 Sep; 57(5):1062-1073. PubMed ID: 37351842
[TBL] [Abstract][Full Text] [Related]
14. Healthcare professionals and pharmacovigilance of pediatric adverse drug reactions: a 5-year analysis of Adverse Events Reporting System Database of the Food and Drug Administration.
Bigi C; Tuccori M; Bocci G
Minerva Pediatr (Torino); 2022 Jun; 74(3):272-280. PubMed ID: 28211644
[TBL] [Abstract][Full Text] [Related]
15. Review of FDA Amendments Act Section 921 Experience in Posting Data-mining Results from the FAERS Database.
Beninger P; Murray M
Clin Ther; 2021 Feb; 43(2):380-395. PubMed ID: 33504449
[TBL] [Abstract][Full Text] [Related]
16. The Weber effect and the United States Food and Drug Administration's Adverse Event Reporting System (FAERS): analysis of sixty-two drugs approved from 2006 to 2010.
Hoffman KB; Dimbil M; Erdman CB; Tatonetti NP; Overstreet BM
Drug Saf; 2014 Apr; 37(4):283-94. PubMed ID: 24643967
[TBL] [Abstract][Full Text] [Related]
17. Characterization and corroboration of safety signals identified from the US Food and Drug Administration Adverse Event Reporting System, 2008-19: cross sectional study.
Dhodapkar MM; Shi X; Ramachandran R; Chen EM; Wallach JD; Ross JS
BMJ; 2022 Oct; 379():e071752. PubMed ID: 36198428
[TBL] [Abstract][Full Text] [Related]
18. Are finasteride-related penile curvature/Peyronie's disease Adverse Event Reports worthy of further clinical investigation? Disproportionality analysis based on both the Food and Drug Administration (FDA) and the European Medicines Agency (EMA) pharmacovigilance databases.
Schifano N; Capogrosso P; Boeri L; Fallara G; Chiappini S; Rewhorn M; Cakir OO; Harvey H; Castiglione F; Alnajjar HM; Muneer A; Deho' F; Schifano F; Montorsi F; Salonia A
Int J Impot Res; 2023 Aug; 35(5):465-471. PubMed ID: 35513712
[TBL] [Abstract][Full Text] [Related]
19. Adverse Drug Reaction Risk Measures: A Comparison of Estimates from Drug Surveillance and Randomised Trials.
Beau-Lejdstrom R; Crook S; Spanu A; Yu T; Puhan MA
Pharmaceut Med; 2019 Aug; 33(4):331-339. PubMed ID: 31933187
[TBL] [Abstract][Full Text] [Related]
20. Metformin adverse event profile: a pharmacovigilance study based on the FDA Adverse Event Reporting System (FAERS) from 2004 to 2022.
Du Y; Zhu J; Guo Z; Wang Z; Wang Y; Hu M; Zhang L; Yang Y; Wang J; Huang Y; Huang P; Chen M; Chen B; Yang C
Expert Rev Clin Pharmacol; 2024; 17(2):189-201. PubMed ID: 38269492
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
